Premium
Effect of a glucagon receptor antibody (REMD‐477) in type 1 diabetes: A randomized controlled trial
Author(s) -
Pettus Jeremy,
Reeds Dominic,
Cavaiola Tricia S.,
Boeder Schafer,
Levin Michelle,
Tobin Garry,
Cava Edda,
Thai Dung,
Shi Jim,
Yan Hai,
Bautista Edgar,
McMillan John,
Unger Roger,
Henry Robert R.,
Klein Samuel
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13202
Subject(s) - medicine , placebo , dosing , type 2 diabetes , adverse effect , diabetes mellitus , randomized controlled trial , glucagon , clinical endpoint , clinical trial , glucagon receptor , insulin , gastroenterology , pharmacology , endocrinology , pathology , alternative medicine
The aim of the current study (Clinical trial reg. no. NCT02715193, clinicaltrials.gov ) was to study the efficacy and safety of REMD‐477, a glucagon receptor antagonist, in type 1 diabetes. This was a randomized controlled trial in which 21 patients with type 1 diabetes were enrolled. Glycaemic control and insulin use were evaluated in outpatient and inpatient settings, before and after a single 70‐mg dose of REMD‐477 (half‐life 7‐10 days) or placebo. Inpatient insulin use was 26% (95% CI, 47%, 4%) lower 1 day after dosing with REMD‐477 than with placebo ( P = .02). Continuous glucose monitoring during post‐treatment days 6 to 12 showed that average daily glucose was 27 mg/dL lower ( P < .001), percent time‐in‐target‐range (70‐180 mg/dL) was ~25% greater (~3.5 h/d) ( P = .001), and percent time‐in‐hyperglycaemic‐range (> 180 mg/dL) was ~40% lower (~4 h/d) ( P = .001) in the REMD‐477 group than in the placebo group, without a difference in percent time‐in‐hypoglycaemic‐range (<70 mg/dL). No serious adverse events were reported. Glucagon receptor antagonism decreases insulin requirements and improves glycaemic control in patients with type 1 diabetes.